Paramount-Warner Bros. Merger Delayed Until 2027 Amid Antitrust Lawsuit 
Serica Energy to Acquire Pharos Energy for £145.7M, Sending PHARP Shares Soaring 
Uber Stock Falls as Waymo Plans to End Robotaxi Partnership by 2028 
Oracle Stock Rises After Winning Up to $6.99 Billion U.S. Defense Software Contract 
OpenAI AI Agent Reportedly Breached Hugging Face, Raising AI Safety Concerns 
SpaceX Stock Slump Wipes Out Nearly $700 Billion From Elon Musk’s Paper Wealth 
AMD Unveils Helios AI Servers to Challenge Nvidia as OpenAI Adopts New Platform 
Zabka Shares Drop 10% as Seven & i Abandons Investment Plans 
CATL Shares Jump as $5.6 Billion Buyback Signals Confidence in Long-Term Growth 
CXMT IPO Debut in Shanghai Puts $85.5 Billion Chipmaker in Spotlight 
SAP Beats Q2 Revenue Estimates as Cloud Backlog and Business AI Demand Drive Growth. 
Johnson & Johnson Proposes $5.5 Billion Talc Settlement to Resolve U.S. Ovarian Cancer Lawsuits 
Rubio Rejects AI ‘Kill Switch’ Claims as U.S. Defends American Technology Abroad 
ASML, Applied Materials Slide as China DUV Chip Equipment Breakthrough Sparks Market Jitters 
Intel Stock Slips After Earnings Rally Despite Strong AI-Driven Revenue Growth 
Trump Administration Monitors OpenAI Incident as Lawmakers Push AI Kill Switch Bill 
AstraZeneca Q2 Earnings Beat Forecasts as Oncology Growth Supports 2026 Outlook 
SAN ANTONIO, Texas, May 03, 2017 -- bioAffinity Technologies announced that the European Patent Office (EPO) has issued a patent that protects the Company’s proprietary CyPath® technology for the early detection of lung cancer through 2030.
Titled “System and Method for Analyzing Samples Labeled with 5, 10, 15, 20 Tetrakis (4-Carboxyphenyl) Porphine (TCPP),” the EPO patent for bioAffinity’s platform test for early cancer detection will significantly increase bioAffinity’s intellectual property (IP) portfolio that currently consists of 43 awarded patents in 22 countries.
bioAffinity’s porphyrin-based CyPath® bio-label preferentially binds to cancer cells, giving them a distinctive fluorescence that is detectable and measurable by flow cytometry. CyPath® Lung, bioAffinity’s initial product, is designed to be a highly accurate, non-invasive, early-stage lung cancer diagnostic for use by patients at risk for lung cancer.
“According to the World Health Organization, nearly 30 percent of European adults are smokers, and smoking among adolescents is on the rise,” bioAffinity President and CEO Maria Zannes said. “Tobacco use causes 16 percent of all deaths in the adult population over 30 years of age. We expect our CyPath® product to have a significant positive impact on early detection of lung cancer in the European Union.”
bioAffinity is focused on the commercialization of accurate, non-invasive diagnostics and life-saving targeted therapeutics for multiple cancers. CyPath® Lung is a simple and cost-effective diagnostic, which will make it particularly valuable in countries with large populations and broad economic and social demographics.
About bioAffinity Technologies, Inc.
bioAffinity Technologies, Inc. (www.bioaffinitytech.com) is a privately held development-stage company addressing the significant unmet need for non-invasive, early-stage cancer diagnosis and treatment. The Company develops proprietary in-vitro diagnostic tests and targeted cancer therapeutics using breakthrough technology that preferentially targets cancer cells. Research and optimization of its platform technology is conducted in bioAffinity Technologies’ laboratories and at the University of Texas Health Science Center at San Antonio through a collaborative research agreement. The Company’s platform technology will be developed to diagnose, monitor and treat many cancers.
Contact: Maria Zannes, 505.400.9747
